FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma.

被引：3
|
作者：
Kilburn, Lindsay Baker
Jabado, Nada
Franson, Andrea
Chi, Susan N.
Fisher, Michael J.
Hargrave, Darren R.
Hansford, Jordan R.
Ziegler, David S.
Landi, Daniel
Kang, Hyoung Jin
Gerber, Nicolas U.
Yalon-Oren, Michal
Cornelio, Izzy
Blackman, Samuel C.
Cox, Michael Craig
Witt, Olaf
Prados, Michael
Mueller, Sabine
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS10056
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS10056
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study
    Kilburn, Lindsay Baker
    Khuong-Quang, Dong-Anh
    Nysom, Karsten
    Landi, Daniel B.
    Ziegler, David Simon
    Driever, Pablo Hernaiz
    Leary, Sarah
    Bailey, Simon
    Van der Lugt, Jasper
    Perreault, Sebastien
    Waanders, Angela Jae
    Baxter, Patricia Ann
    Witt, Olaf
    Hargrave, Darren R.
    McCowage, Geoffrey Brian
    Zhao, Xin
    Da Costa, Daniel
    Cox, Michael Craig
    Manley, Peter
    Hansford, Jordan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] FIREFLY-1 (PNOC026): PHASE 2 STUDY OF PAN-RAF INHIBITOR TOVORAFENIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RAF-ALTERED RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA OR ADVANCED SOLID TUMORS
    Kilburn, Lindsay
    Landi, Daniel
    Leary, Sarah
    Ziegler, David
    Baxter, Patricia
    Franson, Andrea
    McCowage, Geoffrey
    Waanders, Angela
    Van der Lugt, Jasper
    Oren, Michal Yalon
    Gerber, Nicolas
    Gottardo, Nicholas
    Dong-Anh Khuong-Quang
    Nysom, Karsten
    Bailey, Simon
    Driever, Pablo Hernaiz
    Perreault, Sebastien
    Witt, Olaf
    Hahn, Seungmin
    Hargrave, Darren
    Hassall, Timothy
    Jabado, Nada
    Kang, Hyoung Jin
    Larouche, Valerie
    Toledano, Helen
    Kline, Cassie
    Abdelbaki, Mohamed
    Chi, Susan
    Gardner, Sharon
    Whipple, Nicholas
    Mueller, Sabine
    Blackman, Samuel
    Zhao, Xin
    Da Costa, Daniel
    Cox, Michael
    Packer, Roger
    Hansford, Jordan
    NEURO-ONCOLOGY, 2022, 24 : 89 - 89
  • [3] The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial
    Kilburn, Lindsay B.
    Khuong-Quang, Dong-Anh
    Hansford, Jordan R.
    Landi, Daniel
    van der Lugt, Jasper
    Leary, Sarah E. S.
    Driever, Pablo Hernaiz
    Bailey, Simon
    Perreault, Sebastien
    McCowage, Geoffrey
    Waanders, Angela J.
    Ziegler, David S.
    Witt, Olaf
    Baxter, Patricia A.
    Kang, Hyoung Jin
    Hassall, Timothy E.
    Han, Jung Woo
    Hargrave, Darren
    Franson, Andrea T.
    Yalon Oren, Michal
    Toledano, Helen
    Larouche, Valerie
    Kline, Cassie
    Abdelbaki, Mohamed S.
    Jabado, Nada
    Gottardo, Nicholas G.
    Gerber, Nicolas U.
    Whipple, Nicholas S.
    Segal, Devorah
    Chi, Susan N.
    Oren, Liat
    Tan, Enrica E. K.
    Mueller, Sabine
    Cornelio, Izzy
    McLeod, Lisa
    Zhao, Xin
    Walter, Ashley
    Da Costa, Daniel
    Manley, Peter
    Blackman, Samuel C.
    Packer, Roger J.
    Nysom, Karsten
    NATURE MEDICINE, 2024, 30 (01) : 207 - +
  • [4] FIREFLY-1 (PNOC 026): A phase 2 study to evaluate the safety and efficacy of tovorafenib (DAY101) in pediatric patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.
    Landi, Daniel B.
    Ziegler, David S.
    Franson, Andrea Flynn
    Baxter, Patricia Ann
    Leary, Sarah
    Larouche, Valerie
    Waanders, Angela Jae
    Van der Lugt, Jasper
    McCowage, Geoffrey Brian
    Doz, Francois
    Jabado, Nada
    Schiavello, Elisabetta
    Zapotocky, Michal
    Cornelio, Izzy
    Blackman, Samuel C.
    Da Costa, Daniel
    Cox, Michael Craig
    Witt, Olaf
    Kilburn, Lindsay Baker
    Hansford, Jordan R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] CLINICAL ACTIVITY OF PAN-RAF INHIBITOR TOVORAFENIB IN THE REGISTRATIONAL PEDIATRIC LOWGRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY
    Kilburn, Lindsay
    Khuong-Quang, Dong-Anh
    Nysom, Karsten
    Landi, Daniel
    Ziegler, David
    Driever, Pablo Hernaiz
    Leary, Sarah
    Bailey, Simon
    Van der Lugt, Jasper
    Perreault, Sebastien
    Waanders, Angela
    Baxter, Patricia
    Witt, Olaf
    Hargrave, Darren
    McCowage, Geoffrey
    Zhao, Xin
    Da Costa, Daniel
    Cox, Michael
    Manley, Peter
    Hansford, Jordan
    NEURO-ONCOLOGY, 2023, 25
  • [6] PHASE I TRIAL OF DAY101 IN PEDIATRIC PATIENTS WITH RADIOGRAPHICALLY RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA (LGG)
    Wright, Karen
    Krzykwa, Emily
    Greenspan, Lianne
    Chi, Susan
    Yeo, Kee Kiat
    Prados, Michael
    Mueller, Sabine
    Haas-Kogan, Daphne
    NEURO-ONCOLOGY, 2020, 22 : 46 - 46
  • [7] CLINICAL ACTIVITY OF RAF INHIBITOR TOVORAFENIB ACCORDING TO PRIOR MAPK INHIBITOR TREATMENT IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY
    Dong-Anh Khuong-Quang
    Nysom, Karsten
    Landi, Daniel
    Ziegler, David
    Driever, Pablo Hernaiz
    Leary, Sarah
    Bailey, Simon
    van der Lugt, Jasper
    Perreault, Sebastien
    Waanders, Angela
    Baxter, Patricia
    Witt, Olaf
    Hargrave, Darren
    McCowage, Geoffrey
    Hansford, Jordan
    Toledano, Helen
    Oren, Liat
    Tan, Enrica E. K.
    Gerber, Nicolas
    Kang, Hyoung Jin
    Larouche, Valerie
    Abdelbaki, Mohamed S.
    Cornelio, Izzy
    Kim, Yeonhee
    Walter, Ashley
    Manley, Peter
    Kilburn, Lindsay
    NEURO-ONCOLOGY, 2023, 25
  • [8] CLINICAL ACTIVITY AND SAFETY OF THE RAF INHIBITOR TOVORAFENIB IN PATIENTS WITH OPTIC PATHWAY GLIOMAS IN THE REGISTRATIONAL PEDIATRIC LOW-GRADE GLIOMA ARM OF THE PHASE 2 FIREFLY-1 (PNOC026) STUDY
    Nysom, Karsten
    Kilburn, Lindsay
    Leary, Sarah
    Landi, Daniel
    de Vos-Kerkhof, E.
    Perreault, Sebastien
    Witt, Olaf
    Ziegler, David
    Driever, Pablo Hernaiz
    Franson, Andrea
    Baxter, Patricia
    Whipple, Nicholas S.
    Kline, Cassie
    Segal, Devorah
    Jabado, Nada
    Bailey, Simon
    McCowage, Geoffrey
    Hansford, Jordan
    Dong-Anh Khuong-Quang
    Gottardo, Nicholas
    Hassall, Timothy
    Han, Jung Woo
    Oren, Michal Yalon
    Chi, Susan
    Lee, Vai
    McLeod, Lisa
    Qiu, Jiaheng
    Walter, Ashley
    Manley, Peter
    Hargrave, Darren
    NEURO-ONCOLOGY, 2023, 25
  • [9] The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial (vol 30, pg 207, 2024)
    Kilburn, Lindsay B.
    Khuong-Quang, Dong-Anh
    Hansford, Jordan R.
    Landi, Daniel
    van der Lugt, Jasper
    Leary, Sarah E. S.
    Driever, Pablo Hernaiz
    Bailey, Simon
    Perreault, Sebastien
    McCowage, Geoffrey
    Waanders, Angela J.
    Ziegler, David S.
    Witt, Olaf
    Baxter, Patricia A.
    Kang, Hyoung Jin
    Hassall, Timothy E.
    Han, Jung Woo
    Hargrave, Darren
    Franson, Andrea T.
    Oren, Michal Yalon
    Toledano, Helen
    Larouche, Valerie
    Kline, Cassie
    Abdelbaki, Mohamed S.
    Jabado, Nada
    Gottardo, Nicholas G.
    Gerber, Nicolas U.
    Whipple, Nicholas S.
    Segal, Devorah
    Chi, Susan N.
    Oren, Liat
    Tan, Enrica E. K.
    Mueller, Sabine
    Cornelio, Izzy
    McLeod, Lisa
    Zhao, Xin
    Walter, Ashley
    Da Costa, Daniel
    Manley, Peter
    Blackman, Samuel C.
    Packer, Roger J.
    Nysom, Karsten
    NATURE MEDICINE, 2024, 30 (05) : 1500 - 1500
  • [10] Type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma (pLGG): Reversible decreases in growth velocity in the phase 2 FIREFLY-1 trial
    Kline, Cassie
    Waanders, Angela Jae
    Ziegler, David Simon
    Kilburn, Lindsay Baker
    Nysom, Karsten
    van der Lugt, Jasper
    Hassall, Timothy E.
    Gerber, Nicolas U.
    Segal, Devorah
    Larouche, Valerie
    Mueller, Sabine
    Walter, Ashley
    Manley, Peter
    McLeod, Lisa
    Landi, Daniel B.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345